MPD (Myeloproliferative Disorders) Foundation: Drug Discovery News Archive

Drug Discovery News Archive

	Incyte's JAK2 Inhibitor Demonstrates Clinical Benefit for Myelofibrosis Patients in Ongoing Clinical Trial
	UCSD, TargeGen team-up on blood disease treatment
	Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders - Clinical Study to Commence Late This Year
	Incyte Reports Success in Multiple Clinical Programs; Expands JAK Inhibitor Program
	TargeGen Announces Initiation of JAK2 Inhibitor TG101348 Trial for Myeloproliferative Disorder Patients
	JAK2 Inhibitor Shows Potent Activity in Cells from MPD Patients
	Exelixis Reports Data from Ongoing Phase 1 Study of XL019 to Treat Myelofibrosis
	TargeGen Announces Planned Initiation of Clinical Trial for JAK2 Inhibitor TG101348 i n Myeloproliferative Disorder Patients
	Exelixis Files Ind for Anti-Cancer Drug
	Exelixis Winning Phase I Race
	Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options

	Novartis drug wins expanded FDA approval

You will need Adobe Reader to view these documents. Download it here for free.